Chronic benign CD8+ proliferation is a rare syndrome that can take the form of a variety of other diseases. Peripheral adenopathy, cytopenia, and infiltration of the liver, kidneys, bowels, or other organs are the most common clinical presentations of the syndrome. CD8+ expansion can be clonal and nonclonal. It generally occurs in patients with innate or acquired immunodeficiency (HIV+) or in patients receiving immunosuppressive therapy. It has been found repeatedly in patients who developed severe hypogammaglobulinemia after treatment with rituximab. Diagnosis of the disease can be difficult because it can mimic relapse of a lymphoma, and a common biopsy examination cannot identify the problem at first. The authors describe a case of a patient pretreated with rituximab who developed agammaglobulinemia and peripheral adenopathy. Biopsy of an enlarged lymph node showed "reactive lymphadenitis." Additionally, a flow-cytometric examination revealed a pathological population of CD8+ lymphocytes. The treatment, which differed from treatments of lymphoma relapse, consisted of corticosteroids and IVIG substitutions and has led to a regression of clinical symptoms. With more frequent usage of rituximab, one can expect increased occurrence of a very rare CD8+ expansion that can reliably emulate the relapse of a lymphoma.

Department of Hematology and Oncology University Hospital Brno Faculty of Medicine Masaryk University Brno Brno Czech Republic

Department of Molecular Biology and Genetics University Hospital Brno Faculty of Medicine Masaryk University Brno Brno Czech Republic

Department of Pathology University Hospital Brno Faculty of Medicine Masaryk University Brno Brno Czech Republic

Zobrazit více v PubMed

Ghrenassia E., Roulin L., Aline-Fardin A., et al. The spectrum of chronic CD8+ T-cell expansions: clinical features in 14 patients. PLoS One. 2014;9(3):1–10. doi: 10.1371/journal.pone.0091505. PubMed DOI PMC

Pereira B. I., Akbar A. N. Convergence of innate and adaptive immunity during human aging. Frontiers in Immunology. 2016;7:p. 445. doi: 10.3389/fimmu.2016.00445. PubMed DOI PMC

Brugnoni D., Prati E., Malacarne F., Gorla R., Airò P., Cataneo R. The primary response to HIV infection is characterized by an expansion of activated CD8+ CD28− cells. AIDS. 1996;10(1):104–105. doi: 10.1097/00002030-199601000-00017. PubMed DOI

Mudd J. C., Lederman M. M. CD8 T cell persistence in treated HIV infection. Current Opinion in HIV and AIDS. 2014;9(5):500–505. doi: 10.1097/coh.0000000000000086. PubMed DOI PMC

Smith P. R., Cavenagh J. D., Milne T., et al. Benign monoclonal expansion of CD8+ lymphocytes in HIV infection. Journal of Clinical Pathology. 2000;53(3):177–181. doi: 10.1136/jcp.53.3.177. PubMed DOI PMC

Ghrenassia E., Martis N., Boyer J., Burel-Vandenbos F., Mekinian A., Coppo P. The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. Journal of Autoimmunity. 2015;59:19–25. doi: 10.1016/j.jaut.2015.01.010. PubMed DOI

Viallard J.-F., Ruiz C., Guillet M., Pellegrin J.-L., Moreau J.-F. Perturbations of the CD8+ T-cell repertoire in CVID patients with complications. Results in Immunology. 2013;3:122–128. doi: 10.1016/j.rinim.2013.05.004. PubMed DOI PMC

Szablewski V., René C., Costes V. Indolent cytotoxic T cell lymphoproliferation associated with nodular regenerative hyperplasia: a common liver lesion in the context of common variable immunodeficiency disorder. Virchows Archiv. 2015;467(6):733–740. PubMed

Ghielmini M., Vitolo U., Kimby E., et al. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) Annals of Oncology. 2013;24(3):561–576. doi: 10.1093/annonc/mds517. PubMed DOI PMC

Griffin M. M., Morley N. Rituximab in the treatment of non-Hodgkin’s lymphoma—a critical evaluation of randomized controlled trials. Expert Opinion on Biological Therapy. 2013;13(5):803–811. doi: 10.1517/14712598.2013.786698. PubMed DOI

Zinzani P. L., Marchetti M., Billio A., et al. SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. American Journal of Hematology. 2013;88(3):185–192. doi: 10.1002/ajh.23372. PubMed DOI

Casulo C., Maragulia J., Zelenetz A. D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clinical Lymphoma Myeloma and Leukemia. 2013;13(2):106–111. doi: 10.1016/j.clml.2012.11.011. PubMed DOI PMC

Cattaneo C., Spedini P., Casari S., et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leukemia & Lymphoma. 2006;47(6):1013–1017. doi: 10.1080/10428190500473113. PubMed DOI

Nabhan C., Ollberding N. J., Villines D., et al. A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leukemia & Lymphoma. 2014;55(6):1288–1294. doi: 10.3109/10428194.2013.839787. PubMed DOI

Irie E., Shirota Y., Suzuki C., et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. International Journal of Hematology. 2010;91(3):501–508. doi: 10.1007/s12185-010-0528-6. PubMed DOI